U.S. markets closed
  • S&P Futures

    4,164.50
    -11.75 (-0.28%)
     
  • Dow Futures

    33,987.00
    -94.00 (-0.28%)
     
  • Nasdaq Futures

    13,989.75
    -39.75 (-0.28%)
     
  • Russell 2000 Futures

    2,251.40
    -7.60 (-0.34%)
     
  • Crude Oil

    62.88
    -0.25 (-0.40%)
     
  • Gold

    1,777.20
    -3.00 (-0.17%)
     
  • Silver

    26.00
    -0.10 (-0.40%)
     
  • EUR/USD

    1.1972
    -0.0009 (-0.07%)
     
  • 10-Yr Bond

    1.5730
    +0.0430 (+2.81%)
     
  • Vix

    16.25
    -0.32 (-1.93%)
     
  • GBP/USD

    1.3822
    -0.0018 (-0.13%)
     
  • USD/JPY

    108.6990
    -0.0840 (-0.08%)
     
  • BTC-USD

    55,954.46
    -5,425.28 (-8.84%)
     
  • CMC Crypto 200

    1,264.23
    -127.48 (-9.16%)
     
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • Nikkei 225

    29,683.37
    +40.67 (+0.14%)
     

Express Scripts to maintain availability of AbbVie's hep C drug

Oct 28 (Reuters) - Pharmacy benefit manager Express Scripts Holding Co said the potential risk of liver injury from AbbVie' hepatitis C treatments has not impacted the availability of the treatment for patients for whom it is safe and effective.

The Food and Drug Administration said last week AbbVie Inc had identified cases of hepatic decompensation and liver failure in patients with liver cirrhosis who were taking the medicines.

(Reporting by Ankur Banerjee in Bengaluru; Editing by Savio D'Souza)